Analysts Set Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) PT at $79.86

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) has been given an average recommendation of “Moderate Buy” by the nine analysts that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation, five have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $79.8571.

A number of brokerages have commented on TARS. HC Wainwright boosted their price target on Tarsus Pharmaceuticals from $72.00 to $88.00 and gave the company a “neutral” rating in a research note on Monday, October 20th. Guggenheim upped their target price on Tarsus Pharmaceuticals from $84.00 to $87.00 and gave the company a “buy” rating in a research report on Wednesday, November 5th. Zacks Research raised shares of Tarsus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Friday, January 23rd. Wall Street Zen upgraded shares of Tarsus Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. Finally, Barclays initiated coverage on shares of Tarsus Pharmaceuticals in a research note on Monday, December 8th. They issued an “overweight” rating and a $100.00 price objective on the stock.

Tarsus Pharmaceuticals Stock Performance

TARS opened at $66.86 on Wednesday. The company has a market cap of $2.84 billion, a P/E ratio of -33.10, a price-to-earnings-growth ratio of 0.95 and a beta of 0.57. The company has a quick ratio of 4.25, a current ratio of 4.29 and a debt-to-equity ratio of 0.22. The firm’s 50-day moving average price is $76.97 and its 200-day moving average price is $65.94. Tarsus Pharmaceuticals has a 52-week low of $38.51 and a 52-week high of $85.25.

Tarsus Pharmaceuticals (NASDAQ:TARS) last issued its quarterly earnings results on Tuesday, November 4th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.05. The business had revenue of $118.70 million for the quarter, compared to analyst estimates of $114.22 million. Tarsus Pharmaceuticals had a negative net margin of 22.17% and a negative return on equity of 26.29%. As a group, equities analysts anticipate that Tarsus Pharmaceuticals will post -3.17 EPS for the current fiscal year.

Insider Activity

In other Tarsus Pharmaceuticals news, CEO Bobak R. Azamian sold 6,000 shares of the business’s stock in a transaction that occurred on Wednesday, December 24th. The stock was sold at an average price of $82.51, for a total value of $495,060.00. Following the completion of the transaction, the chief executive officer directly owned 857,991 shares of the company’s stock, valued at approximately $70,792,837.41. The trade was a 0.69% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Dianne C. Whitfield sold 7,397 shares of the company’s stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $80.10, for a total value of $592,499.70. Following the completion of the sale, the insider owned 38,958 shares in the company, valued at approximately $3,120,535.80. This represents a 15.96% decrease in their position. The disclosure for this sale is available in the SEC filing. 8.97% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in TARS. F m Investments LLC acquired a new position in shares of Tarsus Pharmaceuticals in the fourth quarter worth about $3,213,000. State of New Jersey Common Pension Fund D acquired a new position in Tarsus Pharmaceuticals in the 4th quarter worth about $885,000. Comerica Bank raised its holdings in Tarsus Pharmaceuticals by 470.0% in the 4th quarter. Comerica Bank now owns 855 shares of the company’s stock worth $70,000 after purchasing an additional 705 shares during the period. D.A. Davidson & CO. purchased a new position in Tarsus Pharmaceuticals during the fourth quarter worth approximately $1,493,000. Finally, Vanguard Group Inc. grew its holdings in Tarsus Pharmaceuticals by 5.6% in the fourth quarter. Vanguard Group Inc. now owns 2,399,560 shares of the company’s stock valued at $196,476,000 after purchasing an additional 127,470 shares during the period. Hedge funds and other institutional investors own 90.01% of the company’s stock.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.